—Challenging Generic Drug Deals “Pharma companies in Europe, U.S. face scrutiny over so-called pay-to-delay tactics.” The European Commission last week claimed that patent settlements between the French drug company Servier and several of its generics competitors may be delaying entry of a generic version of the heart drug perindopril in Europe. The accusation is the latest by officials on both sides of the Atlantic involving the so-called pay-for-delay tactic of drug firms to thwart generic drug competition. The EC lists generic drug manufacturers Teva Pharmaceutical Industries, Niche/Unichem, Matrix (now Mylan Laboratories), Krka, Lupin, and others in its charge that Servier induced competitors to enter settlements in which they agreed to hold off introducing generic versions of perindopril.
by Rick Mullin |
August 06, 2012